Aspen Neuroscience closed a $115 million Series C to accelerate clinical development and manufacturing of its autologous iPSC-derived cell therapy ANPD001 for Parkinson’s disease. The financing will support ongoing Phase I/IIa dosing, scale-up of manufacturing capacity and expansion of the company’s pipeline of personalized iPSC-derived neuroregenerative assets. Aspen has received FDA Fast Track designation for ANPD001 and reported encouraging six‑month safety and efficacy signals from early cohorts, which the company says underpin the new round. Aspen said proceeds will fund clinical and operational milestones, including commercialization readiness. The company highlighted machine‑learning and genomic quality controls integrated into its manufacturing platform to ensure patient‑matched cell product consistency. Investors cited clinical progress and a differentiated autologous approach that avoids chronic immunosuppression as drivers of the round.